Single B cell antibody technology enables the direct isolation of antigen-specific B cells from immunized animals, followed by amplification and recovery of native antibody variable region sequences. Compared with traditional hybridoma methods, this approach shortens the discovery timeline and provides direct access to naturally paired heavy and light chain sequences without the need for cell fusion.<\/p>\n
At AbTriva, our single B cell-based monoclonal antibody development service is designed for projects requiring high-affinity antibody discovery, difficult antigen targeting, or rapid sequence recovery workflows. This platform is particularly useful for antigens that are unstable in hybridoma screening or require precise epitope targeting.<\/p>\n
We integrate antigen preparation, immunization, B cell isolation, single-cell screening, VH\/VL amplification, recombinant expression, and functional validation into a streamlined discovery pipeline.<\/p>\n
<\/p>\n
This platform is especially suitable for:<\/p>\n
For standard screening-heavy workflows or large clone libraries, hybridoma-based approaches may still be preferred depending on project design.<\/p>\n
Our single B cell antibody discovery workflow is built around rapid identification of antigen-specific B cells and direct antibody gene recovery.<\/p>\n
<\/p>\n
Step 1 \u2014 Antigen Preparation & Immunization<\/p>\n
Recombinant protein or peptide antigen design<\/p>\n
Rabbit or mouse immunization<\/p>\n
Serum titer monitoring<\/p>\n
Immune response evaluation<\/p>\n
Step 2 \u2014 Antigen-Specific B Cell Enrichment<\/p>\n
PBMC or splenocyte isolation<\/p>\n
Antigen-specific B cell labeling<\/p>\n
FACS or magnetic enrichment<\/p>\n
Memory B cell enrichment<\/p>\n
Step 3 \u2014 Single B Cell Screening<\/p>\n
Single-cell deposition<\/p>\n
ELISA or fluorescence-based screening<\/p>\n
Positive clone identification<\/p>\n
Step 4 \u2014 VH\/VL Amplification & Sequencing<\/p>\n
Single-cell RT-PCR<\/p>\n
Native heavy\/light chain recovery<\/p>\n
Sequence validation<\/p>\n
Pairing confirmation<\/p>\n
Step 5 \u2014 Recombinant Expression<\/p>\n
HEK293 or CHO expression<\/p>\n
Protein A\/G purification<\/p>\n
Milligram-scale antibody production<\/p>\n
Step 6 \u2014 Functional Validation<\/p>\n
ELISA<\/p>\n
Western Blot<\/p>\n
Immunofluorescence<\/p>\n
Immunohistochemistry<\/p>\n
Flow Cytometry<\/p>\n
Optional SPR\/BLI affinity analysis<\/p>\n
Depending on project scope, typical deliverables include:<\/p>\n
No hybridoma fusion step is required, reducing artifacts introduced by cell fusion instability.<\/p>\n
Early sequence recovery enables earlier recombinant expression and optimization.<\/p>\n
Improved likelihood of capturing rare high-affinity clones.<\/p>\n
Sequences are immediately compatible with downstream engineering and production.<\/p>\n
| Feature<\/th> | Single B Cell<\/th> | Hybridoma<\/th><\/tr>\n |
|---|---|---|
| Timeline<\/td> | Faster<\/td> | Longer<\/td><\/tr>\n |
| Sequence recovery<\/td> | Direct<\/td> | Indirect<\/td><\/tr>\n |
| Stability dependency<\/td> | Low<\/td> | Cell line dependent<\/td><\/tr>\n |
| Clone diversity<\/td> | High<\/td> | Moderate<\/td><\/tr>\n |
| Screening format<\/td> | Single-cell<\/td> | Colony-based<\/td><\/tr>\n<\/table><\/div>\n Technical Considerations & Limitations<\/h2>\nSingle B cell discovery is highly sensitive to immune response quality and sorting efficiency. The following factors may affect success rate:<\/p>\n
|